Loading
NASDAQHealthcareBiotechnology
Latest quote
$49.39
+$0.05 · +0.10%
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
Previous close
$49.39
+$0.05 · +0.10%
After-hours
$49.50
+$0.11 · +0.22%
Sep 8, 7:54 PM ET
Regular session · ET · Market data may be delayed.
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
Day range
Current $49.39
52-week range
Current $49.39
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
40
Expensive
Sentiment
61
Bullish
Risk
34
Moderate Risk
Momentum
67
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
Day range
Current $49.39
52-week range
Current $49.39
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research and development | 16.74M USD | 51.17M USD | 7.85M USD | 1.35M USD |
| Selling, general, and administrative | 13.66M USD | 13.66M USD | 3.53M USD | 1.46M USD |
| Operating expenses | 30.4M USD | 64.83M USD | 11.38M USD | 2.81M USD |
| Interest income | 3.92M USD | 1.72M USD | 811K USD | 73K USD |
| Interest expense | — | — | 4.83M USD | 2.15M USD |
| Depreciation and amortization | 321K USD | 91K USD | 4K USD | 2K USD |
| Operating income | −30.4M USD | −64.83M USD | −11.38M USD | −2.81M USD |
| Net income | −25.21M USD | −63.1M USD | −6.28M USD | −14.35M USD |
Company facts updated Sep 9, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$51.86
5.00% upsideLimited analyst sample: 3 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM27.46M0.03%80.51B USD0.19%$294.67-0.45%
Vanguard Morningstar Total Stock Market ETFVTI27.42M0.00%2.3T USD0.03%$377.6-0.56%
Vanguard Extended Market ETFVXF11.33M0.01%93.7B USD0.05%$241.35-0.54%
State Street SPDR S&P Pharmaceuticals ETFXPH7.41M1.19%617.64M USD0.35%$70.38-0.78%
Schwab U.S. Small-Cap ETFSCHA5.79M0.03%22.93B USD0.03%$34.46-0.26%
iShares Russell 2000 Value ETFIWN5.26M0.04%14.61B USD0.24%$222.76-0.83%
Vanguard Russell 2000 ETFVTWO5.03M0.03%17.4B USD0.06%$119.14-0.40%
iShares Russell 2000 Growth ETFIWO4.71M0.03%14.7B USD0.24%$377.11-0.11%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHSchwab U.S. Small-Cap ETFSCHAiShares Russell 2000 Value ETFIWNVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
